Table 1.
Demographic and clinical data of study subjects.
| CIS/MS n = 31/n = 48 | Controls n = 30 | p-Value | |
|---|---|---|---|
| n Female | 52 (65.8) | 19 (63.3) | n.s.a |
| Age (years) | 32.5 (26.7–41.0) | 36.5 (28.9–46.2) | n.s.b |
| Disease duration (years) | 3.2 (1.0–8.1) | N/A | |
| Time lag first-second MRI (years) | 1.4 (1.0–2.3) | N/A | |
| EDSS | 1.0 (0.0–2.3) | N/A | |
| EDSS at second MRI | 1.0 (0.0–2.0) | N/A | |
| n DMT | 36 (45.6) | N/A | |
| n DMT at second MRI | 52 (77.2) | N/A | |
| ARR | 0.72 (0.42–1.35) | N/A | |
| ARR at second MRI | 0.73 (0.41–1.13) | N/A | |
| Number of Gd+ lesionsc | 2 (1–4) | N/A |
ARR: annualized relapse rate for RRMS patients; CIS: clinically isolated syndrome; DMT: disease-modifying treatment; EDSS: Expanded Disability Status Scale; Gd+: gadolinium positive; MRI: magnetic resonance imaging; MS: multiple sclerosis; n: number of subjects; N/A: not applicable; n.s.: not significant; RRMS: relapsing–remitting multiple sclerosis.
Unless otherwise indicated, data are given for time at the first MRI scan. Values are given as number (%) or as median (interquartile range). Significance (p < 0.05) was assessed between subgroups by Chi-squared testa or Mann–Whitney U test.b
c
Data are given for Gd+ patients only (n = 13/n = 34).